BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Biotech companies at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

149 biotech companies are at BIO-Europe 2026 — 146 presentations on the program. Most represented: Miltenyi Biomedicine (3 on the program), Atrogi (2 on the program), CellNBetter (2 on the program). 129 of them have their own page in this guide. As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Track
Top represented
Showing 1–16 of 149 organizations
OrganizationBIO-Europe 2026 Attendance
Miltenyi Biomedicine
Bergisch Gladbach, Germany
Biotech
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease.
Panel
Tue Nov 10
10:00–10:45
Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making
How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner.
with IGES Institut, Krystal Biotech, EFPIA +1 more
Panel
Tue Nov 10
09:30–09:55
From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients
Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials.
Talk
Wed Nov 11
09:30–09:55
Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies
How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change.
A
Atrogi
Stockholm, Sweden
Biotech
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle.
Panel
Tue Nov 10
16:00–16:45
AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development
How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed.
with PharmSky Research, TransPerfect, Biogen
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with LifeArc, IsomAb, V-Bio Ventures +2 more
CellNBetter
Daejeon, South Korea
Panel
Tue Nov 10
14:00–14:30
Korea's Next Wave: Biotech Innovators to Watch
Korean biotechs present work spanning drug formulation, safety testing, the microbiome, mRNA and gene therapy delivery, and engineered toxins for cosmetic use.
with Startup Colors, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), Cellweaverse +3 more
Talk
Wed Nov 11
10:10–10:20
Technologies and Tools: CellNBetter Inc.
An automated multi-organ cell culture platform, with ready-made kits and analysis, that replaces manual drug testing before clinical trials.
Genmab
Copenhagen, Denmark
Biotech
Danish biotech developing antibody therapeutics for cancer and other diseases.
Panel
Mon Nov 9
13:00–14:00
Navigating partnering and business development in a shifting global landscape
How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples.
with Syneos Health, Biogen, Astellas +2 more
Panel
Tue Nov 10
10:45–11:15
From Partnering Pioneer to Global Biotech Leader: The Next Chapter for European Innovation
How Genmab grew from licensing its discoveries to others into a global company selling its own drugs, and what European biotechs can learn.
with Ropes & Gray
Biotech
Stanford spinout using AI-driven target and drug discovery around extrachromosomal circular DNA in cancer, with a European hub in Berlin.
Panel
Tue Nov 10
09:30–09:55
Biopharma Ecosystem Germany: Spotlight on Innovation Drivers Ready for Take-Off
Five teams from Germany's biotech scene, which spans university research, companies, drug manufacturing and healthcare, show their work and its impact.
with Germany Trade & Invest, Rentschler Biopharma, FGK Clinical Research +1 more
Panel
Tue Nov 10
15:00–15:25
Inside the Incubator: What It Really Takes to Build a Biotech Company Today
What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners.
with Bayer
Tubulis
Munich, Germany
Biotech
Develops antibody-drug conjugates for solid tumors using proprietary conjugation technologies.
Talk
Mon Nov 9
09:00–10:00
Building Your BD Career: What Really Moves the Needle
What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts.
with BD&L Peers Community, Thuja Capital, Merck KGaA +1 more
Keynote
Mon Nov 9
12:00–13:00
Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis
How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets.
with Evaluate, Angelini Ventures, Andera Partners +1 more
Ecosystem InnovationBusiness of Biotech
Panel
Mon Nov 9
15:00–15:25
Unpacking the deal
Business of Biotech · with SPRIND, EQT Life Sciences
Biotech
Develops oral small-molecule allosteric inhibitors for chronic inflammation, fibrosis and cancer, led by an oral inhibitor of IL-1β production.
Panel
Wed Nov 11
10:30–10:55
Building a Clinical Strategy for Rare Disease Therapeutics
How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed.
with Gibela Therapeutics, Cellula Therapeutics
Panel
Wed Nov 11
09:00–09:25
Learning from Failures and Successes in Clinical Trials
What failed and successful clinical trials teach about designing and running better trials, using real examples.
with Cereno Scientific, Digital Medicine Society (DiMe)
CT
Cellula Therapeutics
Epalinges, Switzerland
Biotech
Swiss cell therapy biotech spun out of the University of Geneva.
Panel
Wed Nov 11
10:30–10:55
Building a Clinical Strategy for Rare Disease Therapeutics
How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed.
with Allinky Biopharma, Gibela Therapeutics
Panel
Wed Nov 11
11:00–11:45
Capital with a Mission: Investing Beyond Traditional Venture Models
How mission-driven and foundation investors fund neglected diseases such as glioblastoma and neuroblastoma that venture capital passes over, focusing on Switzerland.
with Remora Biotech, Ampleia, Argobio
Biocytogen
Beijing, China
◆Gold Sponsor
BiotechGold sponsor
Offers humanized mouse models, preclinical services and fully human antibody discovery, and licenses antibody assets including bispecifics and ADCs.
Talk
Tue Nov 10
09:00–09:25
RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Clicks
How Biocytogen combines immunized mice, DNA sequencing, AI screening and lab tests to find fully human antibody candidates in months, not years.
3billion
Seoul, South Korea
Biotech
Rare-disease genetic testing company whose genome analysis is re-run as new disease genes are described, until a patient is diagnosed.
Talk
Mon Nov 9
15:15–15:30
Drug Discovery and Development: 3billion
How a rare disease genetic testing company is using its large store of genome and patient data to find drug targets with AI.
AB
AAVantgarde Bio
Milan, Italy
Biotech
Develops dual-AAV gene therapies for inherited retinal diseases such as Usher syndrome and Stargardt disease.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, Boehringer Ingelheim, Inveready +1 more
Ability Biotherapeutics
Montreal, Canada
Biotech
Develops conditionally activated and multispecific antibodies for cancer and autoimmune diseases, using a generative AI discovery platform.
Talk
Mon Nov 9
09:00–10:00
Building Your BD Career: What Really Moves the Needle
What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts.
with BD&L Peers Community, Thuja Capital, Merck KGaA +1 more
Biotech
Develops and markets medicines for neurological and rare diseases, including Parkinson's disease psychosis and Rett syndrome.
Panel
Tue Nov 10
09:00–09:45
Networks or neurons: What’s next in CNS dealmaking?
What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop.
with Informa, Servier, Biovance Capital +2 more
Aerska
Dublin, Ireland
Biotech
Develops RNAi medicines for neurodegenerative diseases, using antibody shuttles to carry them across the blood-brain barrier.
Panel
Tue Nov 10
09:00–09:45
Networks or neurons: What’s next in CNS dealmaking?
What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop.
with Informa, Servier, Biovance Capital +2 more
AT
Agomab Therapeutics
Ghent, Belgium
Biotech
Develops organ-restricted small molecules for fibrotic diseases, including fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis.
Panel
Mon Nov 9
14:00–14:45
Voices from the IPO Class of ’25/’26: What’s Next?
Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face.
with European Biotechnology Magazine, Andera Partners, HealthCap
Alia Therapeutics
Trento, Italy
Biotech
Italian gene editing start-up working on one-time treatments that correct inherited diseases at the level of the gene.
Chair
Tue Nov 10
09:20–09:30
Chairperson Opening Remarks
Biomanufacturing Strategy

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from biotech companies

Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction